52nd week of 2013 patent applcation highlights part 52 |
Patent application number | Title | Published |
20130345243 | 1H-PYROLLO[3,2-D]PYRIMIDINEDIONE DERIVATIVES - The present invention relates to pyrimidinedione compounds of formula (I), | 2013-12-26 |
20130345244 | LOCAL TREATMENT OF NEUROFIBROMAS - A method for treating a neurofibroma, e.g. dermal neurofibroma, a subdermal neurofibroma, or a superficial plexiform neurofibroma, in a subject in need of such treatment is disclosed. The method comprises locally applying a composition to a neurofibroma either topically or intralesionally. This method does not encompass systemic administration of the composition to the subject to have an effect on the neurofibromas. Compositions useful for such treatments and methods of preparing the compositions are disclosed. | 2013-12-26 |
20130345245 | SUBSTITUTED PYRIMIDINYLPYRROLOPYRIDINONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS - Pyrimidinylpyrrolopyridinone derivatives of formula (I) as defined in the specification, and pharmaceutically acceptable salts thereof, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful, in therapy, in the treatment of diseases associated with a disregulated protein kinase activity, like cancer. | 2013-12-26 |
20130345246 | 2H-Imidazol-4-Amine Compounds and Their Use as Bace Inhibitors - 2H-imidazol-4-amine compounds, therapeutically acceptable salts thereof, processes for preparation thereof, therapeutic uses of such compounds for treating Aβ-related pathologies such as Down's syndrome, β-amyloid angiopathy, Alzheimer's disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with diseases such as Alzheimer's disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration. methods of therapy, and pharmaceutical compositions containing such compounds. | 2013-12-26 |
20130345247 | Cyclohexane-1,2'-Indene-1',2"-Imidazol Compounds and Their Use as Bace Inhibitors - Cyclohexane-1,2′-indene-1′,2″-imidazole compounds, therapeutically acceptable salts thereof, processes for preparation thereof, therapeutic uses of such compounds for treating Aβ-related pathologies such as Down's syndrome, β-amyloid angiopathy, Alzheimer's disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with diseases such as Alzheimer's disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration, methods of therapy using such compounds, and pharmaceutical compositions containing such compounds. | 2013-12-26 |
20130345248 | Cyclohexane-1,2'-Naphthalene-1',2"-Imidazol Compounds and Their Use as Bace - Cyclohexane-1,2′-naphthalene-1′,2″-imidazole compounds, therapeutically acceptable salts thereof, processes for preparation thereof, therapeutic uses of such compounds for treating Aβ-related pathologies such as Down's syndrome, β-amyloid angiopathy, Alzheimer's disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with diseases such as Alzheimer's disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration, methods of therapy using such compounds, and pharmaceutical compositions containing such compounds. | 2013-12-26 |
20130345249 | Formulations for the prevention and treatment of Wolbachia-related disease - The invention encompasses pharmaceutical formulations for the prevention and treatment of | 2013-12-26 |
20130345250 | ANTI-NAUSEA DRUG COMBINATIONS - Methods and compositions are disclosed for reducing Post Operative Nausea and/or Vomiting (PONV) in a human patient in need of general anesthesia. Such methods may include scheduling surgery for the human patient and administering to the patient one or more series of prescribed medicines days during a regimen preceding general anesthesia to condition receptors involved in the nausea and/or vomiting reflex. | 2013-12-26 |
20130345252 | SYNTHESIS AND USE OF DUAL TYROSYL-DNA PHOSPHODIESTERASE I (TDP1)- TOPOISOMERASE I (TOP1) INHIBITORS - The invention described herein pertains to the synthesis and use of certain N-substituted indenoisoquinoline compounds which inhibit the activity Tyrosyl-DNA Phosphodiesterase I (Tdp1) or Topoisomerase I (Top1) or both, or otherwise demonstrate anticancer activity. Also disclosed are novel N-substituted indenoisoquinoline compounds and pharmaceutical compositions comprising the novel N-substituted indenoisoquinoline compounds. | 2013-12-26 |
20130345253 | NOVEL CABERGOLINE DERIVATIVES - Provided herein are novel cabergoline analogs and compositions thereof. In other embodiments, provided herein are methods of treatment, prevention, or amelioration of a variety of medical disorders such as, for example, Parkinson's disease using the compounds and compositions disclosed herein. In still other embodiments, provided herein are methods of antagonizing the 5-HT | 2013-12-26 |
20130345254 | CYCLOHEXANE SUBSTITUTED AMINO CYCLOPENTANE DERIVATIVES AS USEFUL CCR2 ANTAGONISTS - Disclosed are the CCR2 antagonists of Formula I: I or pharmaceutically acceptable salts thereof, wherein A, B, R, and R6 are as defined herein. Also disclosed are pharmaceutical compositions containing the compounds, methods of treatment using the compounds, and compositions to treat diseases or disorders associated with CCR2 activity. | 2013-12-26 |
20130345255 | TRPV1 ANTAGONISTS - Disclosed herein are compounds of formula (I) or pharmaceutically acceptable salts, prodrugs, or combinations thereof, | 2013-12-26 |
20130345256 | N-ETHYL-4-HYDROXYL-1-METHYL-5-(METHYL(2,3,4,5,6-PENTAHYDROXYHEXYL)AMINO)-2- -OXO-N-PHENYL-1,2-DIHYDROQUINOLINE-3-CARBOXAMIDE - The subject invention provides pharmaceutical compositions containing laquinimod or a pharmaceutically acceptable salt thereof, an isolated compound of N-ethyl-4-hydroxyl-1-methyl-5-(methyl(2,3,4,5,6-pentahydroxyhexyl)amino)-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide or a salt thereof, compositions containing N-ethyl-4-hydroxyl-1-methyl-5-(methyl(2,3,4,5,6-pentahydroxyhexyl)amino)-2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide and methods of preparing the same. | 2013-12-26 |
20130345257 | COMPOSITION FOR LUPUS NEPHRITIS AND METHODS OF MAKING AND USING THE SAME - Provided herein are compositions and methods associated with the prevention and treatment of lupus nephritis. In particular, provided herein is a method for delaying onset of active lupus nephritis in a subject at risk for developing active lupus nephritis, comprising periodically administering to the subject an amount of laquinimod effective to delay onset of active lupus nephritis in the subject. Also provided herein are laquinimod (LAQ) and a pharmaceutical composition comprising an amount of LAQ for use in delaying onset of active lupus nephritis in a subject at risk for developing active lupus nephritis. | 2013-12-26 |
20130345258 | AMINO-QUINOLINES AS KINASE INHIBITORS - Disclosed are compounds having the formula: | 2013-12-26 |
20130345259 | Use of Levocabastine for Modulating Generation of Pro-Inflammatory Cytokines - A composition for modulating generation of pro-inflammatory cytokines comprises levocabastine or a pharmaceutically acceptable salt or ester thereof. Such composition is useful for treating or controlling diseases having an inflammatory component, such as ocular diseases that are caused by inflammation or have inflammatory sequelae. | 2013-12-26 |
20130345260 | High Viscosity Liquid Controlled Delivery System and Medical or Surgical Device - The present invention relates to novel nonpolymeric compounds and compositions that form liquid high viscosity materials suitable for the delivery of biologically active substances in a controlled fashion, and for use as medical or surgical devices. The materials can optionally be diluted with a solvent to form a material of lower viscosity, rendering the material easy to administer. This solvent may be water insoluble or water soluble, where the water soluble solvent rapidly diffuses or migrates away from the material in vivo, leaving a higher viscosity liquid material. | 2013-12-26 |
20130345261 | BENZIMIDAZOLE INHIBITION OF BIOFILM FORMATION - The various embodiments relate to a compound comprising: | 2013-12-26 |
20130345262 | METHOD FOR PREVENTION OF STROKE - A method for administering Dabigatran, optionally in the form of a pharmaceutically acceptable salt thereof, to a patient in need of an anticoagulant and/or antithrombotic medicament wherein the daily dose is determined by the dosage regimen including one measurement of dabigatran plasma level. | 2013-12-26 |
20130345263 | USE OF STATHMIN AS A BIOMARKER OF DRUG RESPONSE TO FURAZANOBENZIMIDAZOLES - Use of stathmin as a biomarker for predicting the response, such as resistance, to a compound, wherein the compound is a furazanobenzimidazole compound of general formula (I). | 2013-12-26 |
20130345264 | SUBSTITUTED N-ARYL PYRIDONES - Disclosed herein are methods of administering deuterated pirfenidone and kits thereof. | 2013-12-26 |
20130345265 | Oral Dosage Form Containing A Pde 4 Inhibitor As An Active Ingredient And Polyvinylpyrrolidon As Excipient - Dosage forms for oral administration of a PDE 4 inhibitor whose solubility is slight are described. They contain PVP as binder. | 2013-12-26 |
20130345266 | PEST CONTROL COMPOSITION AND PEST CONTROL METHOD - The present invention provides a pest control composition containing a combination of (E)-1-(2-chloro-1,3-thiazol-5-ylmethyl)-3-methyl-2-nitroguanidine(clothianidin) and an ester compound represented by formula (I). | 2013-12-26 |
20130345267 | METHODS AND COMPOSITIONS FOR MODULATING P300/CBP ACTIVITY - The present invention relates to a method for identifying compounds that modulate the activity of p300/CBP. Compounds of the invention are identified by designing or screening for a compound which binds to at least one amino acid residue of the newly identified lysine-CoA inhibitor binding site, L1 loop, electronegative pocket, or electronegative groove of the HAT domain of p300/CBP and testing the compound for its ability to modulate the activity of p300/CBP. Compositions and methods for preventing or treating diseases or disorders associated with p300/CBP are also provided as is a method for producing a semi-synthetic HAT domain. | 2013-12-26 |
20130345268 | Methods and Compositions for the Treatment of RAS Associated Disorders - The instant disclosure relates to compositions that may be useful as therapeutic agents for the treatment of disorders associated or caused by Ras deregulation or dysregulation, for example, disorders associated with alterations in the NF1 gene such as neurofibromatosis type I, fungal infections such as those caused by | 2013-12-26 |
20130345269 | METHODS OF TREATMENT USING LIPID COMPOUNDS - Methods are disclosed to treat or prevent at least one disease or condition in a subject in need thereof comprising administering a compound of Formula (I): | 2013-12-26 |
20130345270 | METHODS OF TREATING CANCER AND OTHER DISORDERS - Active compounds useful for inhibiting fatty acid synthase in a subject in need thereof are described. The active compounds are, in general, a 5-mercapto-1H-Indazole-4,7-dione or an analog thereof. The compounds are useful for treating subjects afflicted with, cancer, obesity, diabetes, a viral infection, a bacterial infection, a fungal infection, or a protozoal infection. | 2013-12-26 |
20130345271 | POLYMORPHIC, CRYSTALLINE AND MESOPHASE FORMS OF SODIUM 2-(5-BROMO-4-(4-CYCLOPROPYLNAPHTHALEN-1-YL)-4H-1,2,4-TRIAZOL-3-YLTHIO) ACETATE, AND USES THEREOF - Crystalline polymorphs and solid mesophase forms of sodium 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetate are described. In addition, pharmaceutical compositions and uses of such compositions for the treatment of a variety of diseases and conditions are provided. | 2013-12-26 |
20130345272 | Cycloalkyl Ether Compounds and Their Use as Bace Inhibitors - Cycloalkyl ether compounds, therapeutically acceptable salts thereof, processes for preparation thereof, therapeutic uses of such compounds for treating Aβ-related pathologies such as Down's syndrome, β-amyloid angiopathy, Alzheimer's disease, memory loss, attention deficit symptoms associated with Alzheimer's disease, neurodegeneration associated with diseases such as Alzheimer's disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration and pharmaceutical compositions containing such compounds. | 2013-12-26 |
20130345273 | REVERSAL OF DRUG-INDUCED NEUROMUSCULAR BLOCK USING NOVEL MOLECULAR CONTAINERS - Provided are methods for reversing the effects of agents used for muscular immobilization and/or loss of consciousness and/or loss of pain perception. The method comprises administering a composition comprising acyclic CB[n]-type compounds to an individual in need of reversal of the effects of neuromuscular blocking agents and/or anesthetic agents such that the effects of the agent(s) are partially fully reversed. | 2013-12-26 |
20130345274 | ALLANTOIN-CONTAINING SKIN CREAM - An allantoin-containing skin cream composition can comprise allantoin and at least one anionic or nonionic emulsifier that is substantially hydrophilic and is soluble in water. The composition is in the form of an oil-in-water emulsion. The pH of the composition is in a range of from about 3.0 to about 6.0; preferably, the pH of the composition is from about 5.0 to about 6.0. The composition can further comprise an acidic anionic polymer. A preferred acidic anionic polymer is a carboxypolymethylene polymer. The composition can further comprise a carbohydrate polymer such as galactoarabinan, polygalactose or polyarabinose. The composition can additionally comprise other ingredients such as herbal extracts, an antioxidant component, an emollient component, a chelator, a solvent component, or a preservative component. The composition is useful as a skin protectant. | 2013-12-26 |
20130345275 | 1,3-DIHYDROIMIDAZOLE-2-THIONE DERIVATIVES AS INHIBITORS OF DOPAMINE-BETA-HYDROXYLASE - Compounds of formula I and a method for their preparation are described: | 2013-12-26 |
20130345276 | SYNTHETIC TRITERPENOIDS AND METHODS OF USE IN THE TREATMENT OF DISEASE - The present invention concerns methods for treating and preventing renal/kidney disease, insulin resistance/diabetes, fatty liver disease, and/or endothelial dysfunction/cardiovascular disease using synthetic triterpenoids, optionally in combination with a second treatment or prophylaxis. | 2013-12-26 |
20130345277 | Modulators of GTPase and Use In Relevant Treatment - The present invention relates to molecules which function as selective modulators of the Ras-homologous (Rho) family of small GTPases, in particular, Cdc42 GTPase and their use to treat diseases, for example cancers, including metastatic cancer, genetic and acquired diseases where activation of Cdc42 GTPase plays a pivotal role, such as neurodegenerative diseases, rheumatoid arthritis, atherosclerosis, diabetes type I, autosomal polycystic kidney disease, cystic kidney disease, precystic kidney disease, microbial infections, including | 2013-12-26 |
20130345278 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF ORTHOPOXVIRUS INFECTIONS AND ASSOCIATED DISEASES - Methods of using di, tri, and tetracyclic acylhydrazide derivatives and analogs, as well as pharmaceutical compositions containing the same, for the treatment or prophylaxis of viral infections and diseases associated therewith, particularly those viral infections and associated diseases caused by the orthopoxvirus. | 2013-12-26 |
20130345279 | NOVEL POLYMORPHS OF AZABICYCLOHEXANE - The invention provides polymorphic crystalline forms of acid addition salts of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane designated as polymorph form A, polymorph form B and polymorph form C, where polymorph form A is more thermodynamically stable than the other forms, methods for preparing and using such polymorph forms and pharmaceutical compositions containing such polymorph forms. | 2013-12-26 |
20130345280 | Methods And Compositions Employing Bicifadine For Treating Disability Or Functional Impairment Associated With Acute Pain, Chronic Pain, Or Neuropathic Disorders - Methods and compositions are provided for formulating and administering bicifadine and related compounds to treat or prevent functional impairment and disabilities associated with acute pain, chronic pain, and neuropathic disorders. | 2013-12-26 |
20130345281 | CONJUGATED 3-(INDOLYL)- AND 3-(AZAINDOLYL)-4-ARYLMALEIMIDE COMPOUNDS AND THEIR USE IN TUMOR TREATMENT - The present invention relates to 3-(Indolyl)- and 3-(azaindolyl)-4-phenylmaleimide compounds of formula (I) wherein R | 2013-12-26 |
20130345282 | SUBSTITUTED ISOINDOLINE-1,3-DIONE DERIVATIVES - This invention relates to novel substituted isoindoline-1,3-dione derivatives and pharmaceutically acceptable salts thereof. More specifically, the invention relates to novel substituted isoindoline-1,3-dione derivatives that are analogues of apremilast. This invention also provides compositions comprising a compound of this invention and a carrier and the use of disclosed compounds and compositions in methods of treating diseases and conditions that are beneficially treated by administering apremilast. | 2013-12-26 |
20130345283 | PROCESS FOR THE PREPARATION OF ROTIGOTINE - A process for the preparation of Rotigotine (1) | 2013-12-26 |
20130345284 | siRNA Compositions and Methods for Treatment of HPV and Other Infections - The invention provides siRNA compositions that (1) interfere with viral replication of human papillomavirus (HPV), herpes simplex virus (HSV), and human immunodeficiency virus (HIV) in mucosal tissues, such as genital tissues, and (2) treat fungal infections. The compositions include siRNA molecules that target HPV, complexed with a dendrimer that treats and prevents genital herpes (HSV) and HIV. The compositions also include siRNA molecules that target HPV, complexed with a histidine-lysine (HK) polymer that treats and prevent fungus infection. The combined formulations of siRNA and dendrimer provide treatment of the infections from HPVs, HSVs, and HIVs. The combined formulations of siRNA and HK polymer provide treatment of HPVs and fungus infections. | 2013-12-26 |
20130345285 | Methods and Compositions for Inhibiting the Proliferation of Cancer Cells - A method of decreasing the expression of LIM kinase 1 in a cancer cell comprising; providing an oligonucleotide consisting of the sequence of SEQ ID NO: 1; providing a cancer cell comprising an mRNA encoding LIM kinase 1; and introducing the oligonucleotide into the cancer cell, wherein the oligonucleotide decreases the expression of LIM kinase 1 in the cancer cell. The method also provides compositions of an antisense RNA LIM kinase 1 that can be administered to an individual for the purpose of inhibiting a protein kinase pathway and which further comprises methods for treating and monitoring the proliferation and metastasis of cancer cells. A kit may be used in the detection and treatment of cancer. | 2013-12-26 |
20130345286 | LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF EG5 AND VEGF GENES - This invention relates to compositions containing double-stranded ribonucleic acid (dsRNA) in a liquid particle formulation, methods of using the compositions to inhibit the expression of the Eg5/KSP and VEGF, and methods of using the compositions to treat pathological processes mediated by Eg5/KSP and VEGF expression, such as endometrial cancer. | 2013-12-26 |
20130345287 | METHODS OF ANALYSIS OF POLYMORPHISMS AND USES THEREOF - The present invention provides methods for the assessment of diseases that result from the combined or interactive effects of two or more genetic variants, and in particular for diagnosing risk of developing such diseases in subjects using an analysis of genetic polymorphisms. Methods for the derivation of a net score indicative of a subject's risk of developing a disease are provided. | 2013-12-26 |
20130345288 | INHIBITORS OF THE MIR-15 FAMILY OF MICRO-RNAS - The invention provides chemically modified oligonucleotides capable of inhibiting the expression (e.g., abundance) of miR-15 family miRNAs, including miR-15 | 2013-12-26 |
20130345289 | ADULT STEM CELLS, MOLECULAR SIGNATURES, AND APPLICATIONS IN THE EVALUATION, DIAGNOSIS, AND THERAPY OF MAMMALIAN CONDITIONS - The present invention relates to the identification of a stem cell-specific signature or signatures composed of protein and/or nucleic acid markers expressed by virtue of the position of a cell or cells in the time line of its/their development and the impact of the cells' environment on this signature as it relates to the cells' stem cell potential. The composition and combination of these signatures provides a means of identifying, manipulating and differentiating said adult stem cells and thus, their acquisition and utilization in research, diagnosis, and therapy of normal and pathological conditions. | 2013-12-26 |
20130345290 | PHARMACEUTICAL COMPOSITION CONTAINING L-DNA - The invention relates to the use of an L-DNA which is capable of binding to an L-RNA, in particular in an antisense reaction, and optionally of cleaving the L-RNA in the range of a target sequence of the L-RNA, for preparing a pharmaceutical composition for the treatment of undesired physiological side reactions due to the administration of a therapeutic molecule containing the L-RNA. The L-DNA can alternatively also be used for cleaving an endogenous target RNA or DNA. | 2013-12-26 |
20130345291 | METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF GENE EXPRESSION BY DOUBLE-STRANDED RNA - The invention provides compositions and methods for selectively reducing the expression of a gene product from a desired target gene, as well as treating diseases caused by expression of the gene. The method involves introducing into the environment of a cell an amount of a double-stranded RNA (dsRNA) such that a sufficient portion of the dsRNA can enter the cytoplasm of the cell to cause a reduction in the expression of the target gene. The dsRNA has a first oligonucleotide sequence that is between 26 and about 30 nucleotides in length and a second oligonucleotide sequence that anneals to the first sequence under biological conditions. In addition, a region of one of the sequences of the dsRNA having a sequence length of from about 19 to about 23 nucleotides is complementary to a nucleotide sequence of the RNA produced from the target gene. | 2013-12-26 |
20130345292 | HUMANIZED ANTIBODIES AGAINST THE BETA-AMYLOID PEPTIDE - The invention discloses an isolated antibody that selectively binds to the C-terminal part of Abeta and is humanized or fully human. The antibody of the invention is capable of preventing oligomerisation of Abeta. Furthermore, a method of diagnosis comprising the steps of: (i) Labelling an antibody; (ii) Administering an effective dose of said antibody intranasally or systemically to a subject; and (iii) Detecting the concentration and/or presence of the labelled antibody in body parts of the subject is disclosed. | 2013-12-26 |
20130345293 | METHODS FOR TREATING MULTIPLE SCLEROSIS USING ANTISENSE OLIGONUCLEOTIDES - A method for treating a patient suffering from multiple sclerosis, particularly a relapsing form of multiple sclerosis, comprising periodically administering a pharmaceutical composition comprising a therapeutically effective amount of OLIGONUCLEOTIDE 1 to the patient, thereby treating the patient. | 2013-12-26 |
20130345294 | Light-Switchable Gene Expression System - Provided is a light-switchable gene expression system, comprising: a) a recombinant light-switchable transcription factor-encoding gene, said recombinant light-switchable transcription factor comprising a first polypeptide as the DNA bonding domain, a second polypeptide as the photosensitive domain, and a third polypeptide as the transcription regulatory domain; b) a target transcription unit comprising at least one reaction element recognized and bound by the first polypeptide, a promoter regulated by the third polypeptide and a nucleotide sequence to be transcribed. Also provided is an eukaryotic expression vector comprising said light-switchable gene expression system, and a method for regulating gene expression in a host cell by using the light-switchable gene expression system. Also provided is a reagent kit containing different elements of the light-switchable gene expression system. The light-switchable gene expression system has a quick, effective and powerful induction with little or no toxicity. It is safer than other inducers, and can spatiotemporally control gene expression. | 2013-12-26 |
20130345295 | TARGETED ONCOLYTIC ADENOVIRUS FOR TREATMENT OF HUMAN TUMORS, CONSTRCUTION METHOD AND APPLICATION THEREOF - An oncolytic adenovirus vector and its potential application in cancer treatment and vaccination. The inventive vector (named Ad-TD-hIL12) is derived from the human adenovirus group C type 5, more particularly including deletion of three adenovirus genes E1A-CR2, E1B19K and E3gp-19K, and a fused cDNA sequence of p35 and p40 subunit of human IL12 placed under the control of the E3gp-19K promoter. The invention also includes a method to construct the triple gene-deleted vector (Ad-TD). The Ad-TD-hIL12 and Ad-TD-shIL12 (with a short p40 sequence of human IL 12) vectors can be used as targeted, genetically engineered agents for treatment of various solid tumors, via not only intratumoral injection, and also in intraperitoneal injection, without causing significant side effects, showing a superior antitumor efficacy and safety. | 2013-12-26 |
20130345296 | Compositions Comprising a Taxane for Coating Medical Devices - The present invention relates a pharmaceutical composition comprising a taxane and an inhibitory compound capable of inhibiting the enzyme acetaldehyde dehydrogenase e.g. disulfiram. The pharmaceutical compositions of the invention can be used to coat medical devices such as implants. Such implant can be an expansible hollow part, having at least one opening, which consists of an elastic biocompatible material that comprises elongated micro-cavities in its surface. Medical devices coated with a pharmaceutical composition of the invention exhibit an enhanced transfer of taxane from the surface of said medical device into the target tissue. | 2013-12-26 |
20130345297 | METHOD FOR STABILIZING AMPHIPHILIC BLOCK COPOLYMER MICELLE COMPOSITION CONTAINING POORLY WATER-SOLUBLE DRUG - A method for stabilizing a poorly water-soluble drug-containing amphiphilic block copolymer micelle composition via simplified steps in short time is described. Also described is a stabilized poorly water-soluble drug-containing amphiphilic block copolymer micelle composition having improved stability. | 2013-12-26 |
20130345298 | Multi-Arm Polymeric Prodrug Conjugates of Cabazitaxel-Based Compounds - Among other aspects, provided herein are multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds. Methods of preparing such conjugates as well as methods of administering the conjugates are also provided. Upon administration to a patient, release of the cabazitaxel-based compound is achieved. | 2013-12-26 |
20130345299 | COMPOSITION COMPRISING (-)-DELTA9-TRANS-TETRAHYDROCANNABINOL - A composition comprising a tetrahydrocannabinol compound, a solvent and an acid, wherein the tetrahydrocannabinol compound may be Δ | 2013-12-26 |
20130345300 | SMALL MOLECULE MODULATORS OF THE COLD AND MENTHOL RECEPTOR TRPM8 - The present invention relates to the use of compounds which are capable of producing a cooling sensation when they are brought into contact with the human body. In particular, the present invention relates to the use of compounds modulating TRPM8, and optionally to the use of compounds selectively exhibiting agonist activity at the TRPM8 channel. Such compounds have applications in many fields, particularly in oral and personal hygiene products and foodstuffs, but also in pharmaceutical composition products, cosmetics, textile products and packaging products. The present invention further relates to products containing such compounds and to the medical use of such compounds. | 2013-12-26 |
20130345301 | SUPPLEMENT COMPOSITION AND METHOD OF USE - The present invention relates to a dietary supplement composition made of: linolenic expeller pressed soybean oil in the range of 65%-85%, Omega 3 (18/12) fish oil 15%-35%, and 1%-20% alpha-tocopherol and a method to use this composition to supplement the diet of a domestic animal, such as a canine or an equine. | 2013-12-26 |
20130345302 | HONOKIOL ANALOGS AND THEIR USE IN TREATING CANCERS - Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are honokiol analogs. The compounds and compositions can be used to treat and/or prevent a wide variety of cancers, including drug resistant cancers. Representative honokiol analogs include diepoxide honokiol analogues. The compounds are believed to function, at least, by inhibiting angiogenesis and/or inducing apoptosis. Thus, the compounds are novel therapeutic agents for a variety of cancers. | 2013-12-26 |
20130345303 | USE OF FERRIC CITRATE IN THE TREATMENT OF CHRONIC KIDNEY DISEASE PATIENTS - Methods of administering ferric citrate to reduce and/or control serum phosphorus levels, increase serum bicarbonate levels, improve one or more iron storage parameters (e.g., increase serum ferritin levels, increase transferrin saturation (TSAT), increase hemoglobin concentration) increase iron absorption, maintain iron stores, treat iron deficiency, treat anemia, reduce the need for IV iron and/or reduce the need for erythropoiesis-stimulating agents (ESAs) in chronic kidney disease patients, are disclosed. | 2013-12-26 |
20130345304 | COMPOUNDS FOR SUPPRESSING A PERIPHERAL NERVE DISORDER INDUCED BY AN ANTI-CANCER AGENT - The present invention provides a medicament that suppresses (or mitigates) various neurological symptoms caused by a peripheral nerve disorder induced by an anti-cancer agent. | 2013-12-26 |
20130345305 | POWDER EMULSIFIER - The present invention relates to an emulsifier comprising vegetable fibrous material with natural or artificial cavities and comprising at least cellulose, hemicellulose, soluble fibrous material and starch. The vegetable fibrous material is based on e.g. potato. The emulsifier also comprises a lipophilic phase constituting a maximum of 75% by weight of the total weight, wherein the emulsifier is in the form of a powder or a paste. The vegetable fibrous material constitutes a support phase in the emulsifier, and the emulsifier also comprises some form of dextrose, dextrose polymer, dextrin or dextrin polymer or a derivate thereof. | 2013-12-26 |
20130345306 | IDENTIFICATION OF C3 COMPLEMENT MOLECULE AT THE SITE OF INJURY TO BLOOD VESSELS IN THE RETINA OF OXYGEN EXPOSED ANIMALS - The invention provides methods to treat oxygen-induced retinopathy using complement factor C3aR antagonists. | 2013-12-26 |
20130345307 | Systems and methods for skin rejuvenation - Systems and methods for skin rejuvenation are disclosed herein. In an embodiment, a skin rejuvenation system includes a unit dose of a booster product that includes active ingredients of ferulic acid and phloretin; a unit dose of at least one exfoliating product that includes active ingredients of ferulic acid and phloretin in combination with fruit acids or alpha hydroxyacids; and a unit dose of a nano-additive product for enhancing penetration of the active ingredients. A method for skin rejuvenation includes applying topically, to a skin surface to be treated, a booster product including active ingredients of ferulic acid and phloretin; applying topically, to the skin surface, at least one exfoliating product including active ingredients of ferulic acid and phloretin in combination with one of fruit acids or alpha hydroxyacids; and applying topically, to the skin surface, a nano-additive product for enhancing penetration of the active ingredients. | 2013-12-26 |
20130345308 | PHARMACEUTICAL AND NUTRACEUTICAL COMPOSITIONS OF ABSCISIC ACID - The invention relates to compositions comprising abscisic acid, and/or salts, derivatives and analogs thereof, and methods of pharmaceutical and/or nutraceutical use. | 2013-12-26 |
20130345309 | MALIC ACID-ENRICHED PLANT EXTRACT - Malic acid-enriched plant extracts useful as food additives are described. | 2013-12-26 |
20130345310 | SOLID COMPOSITION CONTAINING THE INGREDIENT RASAGILINE - The present invention relates to a solid composition containing at least one pharmaceutically compatible auxiliary ingredient and rasagiline or a pharmaceutically compatible salt thereof as an active ingredient. The invention further relates to a method for producing said solid composition and to a medicine comprising said solid composition. | 2013-12-26 |
20130345311 | Synthesis Of Triethylenetetramines - Methods and intermediates for synthesizing triethylenetetramine and salts thereof, as well as novel triethylenetetramine salts and their crystal structure, and triethylenetetramine salts of high purity. | 2013-12-26 |
20130345312 | TREATMENT OF MITOCHONDRIAL DISEASES WITH NAPHTHOQUINONES - Methods of treating, preventing or suppressing symptoms associated with mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), dominant optic atrophy (DOA); mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), Leigh syndrome or Kearns-Sayre Syndrome (KSS) with compounds of Formula (I) are disclosed. Methods of modulating, normalizing, or enhancing energy biomarkers, as well as compounds useful for such methods are also disclosed. | 2013-12-26 |
20130345314 | Compositions and methods for treating a damaged cardiovascular element - In the present invention, the applicants describe methods and compositions of treating damaged cardiovascular elements and cardiovascular conditions including hypotension, atherosclerotic lesions, vulnerable plaque, and acute myocardial infarct. The applicants demonstrate the ability of a biomembrane sealing agent to accumulate on the walls of damaged blood vessels and help improving mean arterial pressure following tissue injury. The applicants describe the use of formulations comprising at least one biomembrane sealing agent and one bioactive agent for prophylactic treatment such as they could be administered concurrently to an invasive therapeutic intervention or after the insult (i.e. post-injury or post-surgery). Alternatively, these methods and compositions could be used to reduce the severity of cardiovascular diseases after onset. | 2013-12-26 |
20130345315 | WATER-RELEASING COSMETIC COMPOSITION - A water-releasing cosmetic composition in the form of an emulsion and process for preparing the cosmetic composition are provided. The cosmetic composition includes an aqueous phase and an oil phase. The aqueous phase includes a hydrating agent at a concentration, by weight, of about 1% to about 50% and a preservative system at a concentration, by weight, based upon weight of the composition. The oil phase includes dimethicone at concentration, by weight of about 1% to about 40%, and an emulsifying crosslinked siloxane elastomer at a concentration, by weight, of about 3% to about 20%, both based upon weight of the composition. The cosmetic composition converts from an emulsion to a plurality of droplets upon rubbing. The process for preparing the water-releasing cosmetic composition includes regular or cold-processing methods to form the emulsion. | 2013-12-26 |
20130345316 | WATER-RELEASING COSMETIC COMPOSITION - A water-releasing cosmetic composition in the form of an emulsion and process for preparing the cosmetic composition are provided. The cosmetic composition includes an aqueous phase and an oil phase. The aqueous phase includes a hydrating agent at a concentration, by weight, of about 1% to about 50% and a preservative system at a concentration of about 0.1 to 3%, by weight, based upon weight of the composition. The oil phase includes dimethicone at concentration, by weight of about 1% to about 40%, and an emulsifying crosslinked siloxane elastomer at a concentration, by weight, of about 3% to about 20%, both based upon weight of the composition. The cosmetic composition has a phase ratio of the aqueous phase to the oil phase of about 1.5 to about 12.0. The cosmetic composition converts from an emulsion to a plurality of droplets upon rubbing. | 2013-12-26 |
20130345317 | WATER-RELEASING COSMETIC COMPOSITION INCLUDING A HYDROPHOBIC SILICA AND A CO-EMULSIFIER - A water-releasing cosmetic composition in the form of an emulsion and process for preparing the cosmetic composition are provided. The cosmetic composition includes an aqueous phase and an oil phase. The aqueous phase includes a hydrating agent at a concentration, by weight, of about 1% to about 50%. The oil phase includes a silicone polymer, an emulsifying crosslinked siloxane elastomer, a hydrophobic silica and a co-emulsifier. The emulsifying crosslinked siloxane elastomer is at a concentration, by weight, of about 3%-20%, based upon weight of the composition. The hydrophobic silica is at a concentration, by weight, of about 0.1%-5%, based upon weight of the composition. The co-emulsifier is at a concentration, by weight, of about 0.01%-1%, based upon weight of the composition. The cosmetic composition converts from an emulsion to a plurality of droplets upon rubbing. | 2013-12-26 |
20130345318 | SILICONE POLYETHERS AND PREPARATION THEREOF FROM POLYETHERS BEARING METHYLIDENE GROUPS - Silicone polyethers and a process for preparation thereof wherein polyethers modified laterally with methylidene groups are reacted with hydrosiloxanes in a hydrosilylation reaction. | 2013-12-26 |
20130345319 | POLYMER HYDROGEL ADHESIVES FORMED WITH MULTIPLE CROSSLINKING MECHANISMS AT PHYSIOLOGIC PH - The present invention encompasses biocompatible reactants, biocompatible product hydrogels, methods of use thereof, and methods of synthesis thereof using a novel crosslinking mechanism between a first reactant compound including an N-Hydroxysuccinimide (NHS) ester group and a second reactant compound including a N-terminal cysteine amine group. In certain embodiments, one or more of the reactant compounds may be a macromonomer. | 2013-12-26 |
20130345320 | Active-Ingredient-Containing Solid Dispersions Based on Diethylaminoethyl Methacrylate Copolymers - Described are solid dispersions of hydrophobic active ingredients and cationic copolymers of N,N-diethylaminoethyl methacrylate and methyl methacrylate in a weight ratio of the monomers of from 35:65 to 55:45. Also described are the preparation and use of such solid dispersions for pharmaceutical dosage forms. | 2013-12-26 |
20130345321 | GENIPIN CROSS-LINKED FIBRIN GELS - The invention provides a genipin cross-linked fibrin gel. The ratio of genipin to fibrin in the gel ranges from about 0.1:1 to about 10:1 (genipin:fibrin). The gel can be hydrogel. The gel further contains proteins from the extracellular matrix that promote cell growth and density in and around the gel. Also provided is method for repairing tissue defects by administering the gel to site of tissue defect. | 2013-12-26 |
20130345322 | DIAGNOSTIC FOR COLORECTAL CANCER - The present invention provides a method for diagnosing or detecting colorectal cancer in a subject, the method comprising determining the presence and/or level of biomarkers selected from IL-8, IGFBP2, MAC2BP, M2PK, IL-13, DKK-3, EpCam, MIP1β, TGFβ1, and TIMP-1. The invention also relates to diagnostic kits comprising reagents for determining the presence and/or level of the biomarkers and methods of detecting or diagnosing colorectal cancer. | 2013-12-26 |
20130345323 | DISPERSING METHOD OF CARBON NANOTUBE, DISPERSING APPARATUS OF CARBON NANOTUBE, AND CARBON NANOTUBE DISPERSION OBTAINED THEREBY - The present disclosure relates to a dispersing method of a carbon nanotube comprising: the first step of mixing a carbon nanotube aggregate, a magnetic material and a dispersant; and the second step of applying a magnetic field to the mixture obtained in the first step to disperse the carbon nanotube aggregate, a dispersing apparatus of a carbon nanotube, and a carbon nanotube dispersion obtained thereby. A carbon nanotube aggregate can be more effectively dispersed without damaging a carbon nanotube by the dispersing method of a carbon nanotube according to the present disclosure. | 2013-12-26 |
20130345324 | PROCESS FOR REFORMING HYDROCARBONS - A process and plant for the production of synthesis gas by a series arrangement of heat exchange reforming and autothermal reforming stages, in which the heat required for the reforming reactions in the heat exchange reforming stage is provided by hot effluent synthesis gas from the autothermal reforming stage. The invention optimizes the operation and control of an arrangement of heat exchange reforming and autothermal reforming stages and involves the introduction of an additional waste heat boiler. | 2013-12-26 |
20130345325 | METHOD FOR PRODUCING METHANOL OR HYDROCARBONS FROM A CARBON MATERIAL, INCLUDING A REFORMING STEP, THE OPERATING CONDITIONS OF WHICH ARE SELECTIVELY ADJUSTED - A method for producing methanol or hydrocarbons is provided. The production method comprises producing a synthesis gas from carbonaceous material, according to a method comprising at least one reforming step, the synthesis gas having a first hydrogen/carbon monoxide molar ratio under the first operating conditions for the reforming operation; producing a stream of hydrogen from a hydrogenated raw material and from a first consumed electric power, the hydrogen stream having a first molar flow rate for said first consumed electric power; and lowering the consumed electric power for producing the hydrogen stream, down to a second electric power below the first electric power and transitioning to second operating conditions different from the first for the reforming operation in order to compensate for the lowering of the molar flow rate of the hydrogen flow, the synthesis gas having a second hydrogen/carbon monoxide molar ratio greater than the first under the second operating conditions. | 2013-12-26 |
20130345326 | PROCESS FOR PRODUCING A SYNTHESIS GAS MIXTURE - Disclosed herein are processes for producing a synthesis gas mixture and for producing an organic chemical product. The process can comprise: (i) steam reforming a feed gas stream comprising one or more hydrocarbons to produce a reformed synthesis gas mixture comprising H | 2013-12-26 |
20130345327 | PROCESS FOR PRODUCING EXPANDABLE PELLETIZED MATERIAL WHICH COMPRISES POLYLACTIC ACID - The invention relates to a process for producing expandable pelletized material which comprises polylactic acid which comprises the following steps:
| 2013-12-26 |
20130345328 | PROCESS FOR THE PREPARATION OF GRANULES BASED ON EXPANDABLE THERMOPLASTIC POLYMERS AND RELATIVE PRODUCT - A particulate polymeric composition capable of being processed to provide expanded articles having a density lower than or equal to 50 g/l and a closed cell content of at least 60% as specified by ASTM D-2856, wherein resulting particulates have a shape factor ranging from 0.6 to 0.99; and wherein the particulate polymeric composition is produced according to a process that prepares expandable granules based on thermoplastic polymers, through a granulation die. | 2013-12-26 |
20130345329 | Rigid Polyurethane Foam and System and Method for Making the Same - An embodiment of a closed-cell polymeric rigid foam may be made using a one-shot method and a reaction system that includes a hydrofluoroalkene physical blowing agent and a polyol mixture having an aminic polyol. The hydrofluoroalkene blowing agent has 3 to 5 carbon atoms and a boiling point between 10° C. and 40° C. at 1 atmosphere pressure. Embodiments of rigid foams may have high closed cell content and are particularly well suited for thermal insulation. | 2013-12-26 |
20130345330 | METHOD FOR PRODUCING FLEXIBLE POLYURETHANE FOAMS - A process for the preparation of polyricinoleic acid esters comprising the step of reaction of ricinoleic acid with an alcohol component which comprises mono- and/or polyfunctional alcohols having a molecular weight of ≧32 g/mol to ≦40 g/mol, wherein the reaction is carried out at least partly in the presence of a catalyst. The amount of catalyst, based on the total weight of the ricinoleic acid and the alcohol component, is in a range of from ≧10 ppm to ≦100 ppm. The reaction is ended when the acid number of the reaction product obtained is ≧5 mg of KOH/g to ≦100 mg of KOH/g. The invention furthermore relates to a polyurethane polymer, in particular a flexible polyurethane foam, which is obtainable using these polyricinoleic acid esters. | 2013-12-26 |
20130345331 | HIGH-CONCENTRATION POLYMER POLYOL AND METHOD FOR ITS PRODUCTION - If it is attempted to produce a polymer polyol at a high concentration, there will be a problem such that during polymerization of a monomer to form fine polymer particles, particles are likely to aggregate one another to form aggregates, and storage stability of the polymer polyol tends to deteriorate. A method for producing a polymer polyol is presented which comprises polymerizing at least one type of ethylenically unsaturated monomer together with a seed particle dispersion, in a polyol, wherein the seed particle dispersion is one obtained by polymerizing an ethylenically unsaturated monomer in the presence of an ethylenically unsaturated macromonomer, a solvent and a chain transfer agent, and the ethylenically unsaturated macromonomer is a reaction product of a specific polyol, an isocyanate compound and an ethylenically unsaturated monomer having a hydroxy group. | 2013-12-26 |
20130345332 | Low Dust, Light Weight Filler Composition - A filler composition for use in a casting formulation, where the filler composition includes a mineral filler, hollow plastic microspheres, and a food grade and non-flammable liquid, and where when the filler composition is mixed with a casting resin an OSHA 8-hour Permissible Exposure Limit set for Particulates Not Otherwise Regulated is not exceeded. | 2013-12-26 |
20130345333 | ADHESIVE FILM, ADHESIVE COMPOSITION FOR THE SAME, AND OPTICAL MEMBER INCLUDING THE SAME - An adhesive film, an adhesive composition for the same, and an optical member including the same, the adhesive film having an index of refraction of about 1.48 or more and a dielectric constant variation of about 30% or less, as expressed by Equation 1: | 2013-12-26 |
20130345334 | CROSS-LINKED POLYMERS AND IMPLANTS DERIVED FROM ELECTROPHILICALLY ACTIVATED POLYOXAZOLINE - One aspect of the invention relates to a biocompatible, covalently cross-linked, polymer that is obtained by reacting an electrophilically activated polyoxazoline (EL-POX) with a nucleophilic cross-linking agent, said electrophilically activated POX comprising m electrophilic groups; and said nucleophilic cross-linking agent comprising n nucleophilic groups, wherein the m electrophilic groups are capable of reaction with the n nucleophilic groups to form covalent bonds; wherein m≧2, n≧2 and m+n≧5; wherein at least one of the m electrophilic groups is a pendant electrophilic group and/or wherein m≧3; and wherein the EL-POX comprises an excess amount of electrophilic groups relative to the amount of nucleophilic groups contained in the nucleophilic cross-linking agent. The invention further relates to biocompatible medical products comprising such a cross-linked POX-polymer. Also provided is a kit for producing a biocompatible, cross-linked POX-polymer. The invention further provides a tissue adhesive medical product comprising at least 1% by weight of dry matter of EL-POX, said EL-POX comprising at least 2 electrophilic groups, including at least one pendant electrophilic group. The polymers according to the invention have excellent implant and/or sealing characteristics. | 2013-12-26 |
20130345335 | RUBBER COMPOSITION, METHOD FOR PRODUCING SAME, AND TIRE - A rubber composition that can obtain a rubber elastic body having small rolling resistance and excellent impact resilience and a method for producing the same, and a tire having small rolling resistance and excellent impact resilience are provided. The rubber composition of the present invention is obtained by kneading a conjugated diene polymer having a functional group bondable to silica, an acylate compound containing metal and silica. In the present invention, a polymer having no functional group bondable to silica is preferably kneaded as a rubber component other than the conjugated diene polymer, together with the conjugated diene polymer having a functional group bondable to silica, the acylate compound containing metal and the silica. | 2013-12-26 |
20130345336 | TIRE, THE TREAD OF WHICH COMPRISES A THERMOPLASTIC POLYURETHANE BLOCK COPOLYMER - A tire, the tread of which comprises a rubber composition comprising at least: as first elastomer, a diene elastomer; as second elastomer, a thermoplastic polyurethane block copolymer with polyurethane blocks and polydiene blocks; 70 to 150 pce of an inorganic reinforcing filler; a plasticizing system comprising: with a content A of 5 to 60 pce, a hydrocarbon resin, the Tg of which is higher than 20° C.; with a content B of 5 to 60 pce, a plasticizer which is liquid at 20° C., and the Tg of which is lower than −20° C.; it being understood that A+B is higher than 30 pce. The use of a thermoplastic polyurethane block copolymer with polyurethane blocks and polydiene blocks, in particular in the presence of high filler and plasticizer contents, in the composition of a tire tread as per the present invention enables tires having improved grip on wet ground to be obtained. | 2013-12-26 |
20130345337 | RUBBER COMPOSITION AND PNEUMATIC TIRE - The present invention provides a rubber composition that can enhance the fuel economy, wet-grip performance, and abrasion resistance in a balanced manner, and a pneumatic tire using this rubber composition. The present invention relates to a rubber composition that contains a rubber component, silica, and a liquid resin having a softening point of −20 to 20° C., wherein the rubber component contains, based on 100% by mass of the rubber component, not less than 5% by mass of a conjugated diene polymer containing a constituent unit based on a conjugated diene and a constituent unit represented by formula (I) below, at least one terminal of the polymer being modified with a specific compound; and an amount of the silica is 5 to 150 parts by mass per 100 parts by mass of the rubber component. | 2013-12-26 |
20130345338 | SYSTEM AND METHOD FOR TREATING AGRICULTURAL SETTINGS - The treatment of an agricultural setting may be implemented by applying an adhesive using a pump sprayer. The agricultural setting may include mulch, pine straw, wood chips, and other materials used in landscaping. The adhesive may be used to keep the agricultural setting in place. For example, the adhesive may keep mulch from moving in heavy winds or during a storm. | 2013-12-26 |
20130345339 | RECYCLED CRUMB RUBBER COATING - The recycled crumb rubber coating is a corrosion-proof coating for piping and the like. The coating is formed from recycled crumb rubber mixed with an epoxy resin and a hardener. Crumb rubber is first mixed with a liquid epoxy resin. An agent for reducing the viscosity of the liquid epoxy resin may also be added. A hardener is then added to this mixture. Finally, powdered crumb rubber is added and mixed to form the recycled crumb rubber coating. The total crumb rubber forms about 23 wt % of the coating. If no viscosity reducing agent is added, then the liquid epoxy resin forms about 51.6 wt % of the coating. If the viscosity reducing agent is added, then the liquid epoxy resin forms about 50.1 wt % of the coating, and the viscosity reducing agent forms about 1.5 wt % of the coating. The hardener forms about 25.4 wt % of the coating. | 2013-12-26 |
20130345340 | Composition for the Optimization of Mineral Building Material Compositions - The present invention relates to compositions which are suitable for optimizing mineral building material compositions so that the flow behaviour and the deaeration of the compositions is positively influenced, as a result of which very smooth, virtually pore-free surfaces can be achieved. The compositions can consist of a mixture or comprise a mixture which contains at least one component (a) which comprises a compound N which displays a wetting action in aqueous cement-containing binder systems and contains at least one further component (b) which comprises a compound E which has antifoam properties in aqueous cement-containing binder systems. The compound N in component a) can preferably be a nonionic or amphoteric surfactant, preferably an alkyl alkoxylate or a betaine. The compound E in component b) can preferably be a polyetherpolysiloxane on a support material. | 2013-12-26 |
20130345341 | MODIFIED CELLULOSE NANOFIBERS, PRODUCTION METHOD THEREOF, AND RESIN COMPOSITION USING SAME - The present invention relates to modified cellulose nanofibers obtained by neutralizing cationic groups of cationic cellulose nanofibers with an anionic additives. Moreover, the present invention relates to a resin composition containing the aforementioned modified cellulose nanofibers and a molding resin, and to a molded body obtained by molding the resin composition. Furthermore, the present invention relates to a production method of modified cellulose nanofibers comprising neutralizing cationic groups of cationic cellulose nanofibers with an anionic additives. | 2013-12-26 |
20130345342 | Bi-Modal Emulsions - A process for preparing bi-modal water emulsions is disclosed comprising: I) forming a mixture comprising; A) 100 parts by weight of a hydrophobic oil, B) 1 to 1000 part by weight of a water continuous emulsion having at least one surfactant, II) admixing additional quantities of the water continuous emulsion and/or water to the mixture from step I) to form a bi-modal emulsion. | 2013-12-26 |
20130345343 | GLASS FIBER SIZING AGENT AND GLASS FIBER-REINFORCED CRYSTALLINE RESIN COMPOSITION - Disclosed is a glass fiber-reinforced crystalline resin composition superior in the surface properties and the mechanical properties of a molded article thereof. Specifically, provided is a glass fiber-reinforced crystalline resin composition containing a glass fiber sizing agent that is an aqueous resin containing an o-sulfobenzimide compound, a crystalline resin, glass fibers, wherein the glass fibers have been treated with the glass fiber sizing agent. An aqueous polyurethane resin is preferred as the aqueous resin. | 2013-12-26 |
20130345344 | ADHESION PROMOTING CURATIVE AND STABILIZER SYSTEM FOR ELASTOMER COMPOSITION - An adhesion promoting curative and stabilizer system for an elastomer comprises:
| 2013-12-26 |